MX2019014465A - Anticuerpos especificos para flt3 y sus usos. - Google Patents
Anticuerpos especificos para flt3 y sus usos.Info
- Publication number
- MX2019014465A MX2019014465A MX2019014465A MX2019014465A MX2019014465A MX 2019014465 A MX2019014465 A MX 2019014465A MX 2019014465 A MX2019014465 A MX 2019014465A MX 2019014465 A MX2019014465 A MX 2019014465A MX 2019014465 A MX2019014465 A MX 2019014465A
- Authority
- MX
- Mexico
- Prior art keywords
- flt3
- antibodies
- invention further
- further relates
- antibodies specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención proporciona anticuerpos que se unen específicamente a FLT3 (Tirosina quinasa tipo Fms 3). La invención proporciona además anticuerpos biespecíficos que se unen a FLT3 y a otro antígeno (por ejemplo, CD3). La invención se refiere además a ácidos nucleicos que codifican anticuerpos, y a métodos para obtener tales anticuerpos (monoespecíficos y biespecíficos). La invención se refiere además a métodos terapéuticos para el uso de estos anticuerpos para el tratamiento de patologías mediadas por FLT3, que incluyen cáncer tal como leucemia mieloide aguda (AML).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762514574P | 2017-06-02 | 2017-06-02 | |
US201862660908P | 2018-04-20 | 2018-04-20 | |
PCT/IB2018/053908 WO2018220584A1 (en) | 2017-06-02 | 2018-05-31 | Antibodies specific for flt3 and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014465A true MX2019014465A (es) | 2020-01-23 |
Family
ID=62751219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014465A MX2019014465A (es) | 2017-06-02 | 2018-05-31 | Anticuerpos especificos para flt3 y sus usos. |
Country Status (16)
Country | Link |
---|---|
US (2) | US11421040B2 (es) |
EP (1) | EP3630841A1 (es) |
JP (2) | JP7234142B2 (es) |
KR (3) | KR102356984B1 (es) |
CN (1) | CN111247167A (es) |
AU (1) | AU2018275359C1 (es) |
BR (1) | BR112019025243A2 (es) |
CA (1) | CA3006798A1 (es) |
CO (1) | CO2019013611A2 (es) |
IL (1) | IL271110A (es) |
MX (1) | MX2019014465A (es) |
PE (1) | PE20191846A1 (es) |
PH (1) | PH12019502640A1 (es) |
RU (1) | RU2758513C2 (es) |
TW (3) | TWI790120B (es) |
WO (1) | WO2018220584A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3352784A4 (en) | 2015-09-23 | 2019-06-26 | Cytoimmune Therapeutics, LLC | FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
EP3630837A1 (en) * | 2017-06-02 | 2020-04-08 | Pfizer Inc | Chimeric antigen receptors targeting flt3 |
JP7449041B2 (ja) | 2018-02-27 | 2024-03-13 | ファイザー・インク | 抗体精製 |
CA3034912A1 (en) | 2018-02-28 | 2019-08-28 | Pfizer Inc. | Il-15 variants and uses thereof |
TWI793325B (zh) | 2018-05-23 | 2023-02-21 | 美商輝瑞大藥廠 | 對cd3具特異性之抗體及其用途 |
EP3796983A2 (en) | 2018-05-23 | 2021-03-31 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
WO2020128638A1 (en) * | 2018-12-18 | 2020-06-25 | Northern Biologics Inc. | Flt3 agonist antibodies and uses thereof |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
AU2020308463A1 (en) * | 2019-06-26 | 2022-02-17 | Ap Biosciences, Inc. | Antibodies for T-cell activation |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies unique to d47, pd-l1 and their uses |
TW202128176A (zh) | 2019-12-18 | 2021-08-01 | 美商輝瑞股份有限公司 | 使用蛋白精胺酸甲基轉移酶5(prmt5)抑制劑之每日一次癌症治療方案 |
AU2021224851A1 (en) * | 2020-02-21 | 2022-09-15 | Harpoon Therapeutics, Inc. | FLT3 binding proteins and methods of use |
WO2021181233A2 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
AU2021255884A1 (en) * | 2020-04-14 | 2022-11-17 | Les Laboratoires Servier | Anti-FLT3 antibodies and compositions |
KR20230004680A (ko) | 2020-04-17 | 2023-01-06 | 시티 오브 호프 | Flt3-양성 악성 종양의 치료를 위한 flt3-표적화된 키메라 항원 수용체 변형 세포 |
KR20230008197A (ko) | 2020-05-13 | 2023-01-13 | 화이자 인코포레이티드 | 암을 치료하기 위한 방법, 요법 및 용도 |
CN111808821B (zh) * | 2020-06-24 | 2022-06-14 | 南方医科大学珠江医院 | Flt3-nkg2d双靶点car-t的构建与制备 |
TW202216779A (zh) | 2020-07-17 | 2022-05-01 | 美商輝瑞股份有限公司 | 治療性抗體類和彼等之用途 |
US20230340137A1 (en) | 2020-09-14 | 2023-10-26 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
CN113621068B (zh) * | 2021-10-11 | 2022-01-07 | 上海恒润达生生物科技股份有限公司 | 一种特异性结合cd276的抗体或其抗原结合片段及其制备方法和应用 |
CN114316060B (zh) * | 2021-12-15 | 2023-06-13 | 北京市肿瘤防治研究所 | 抗人cd19与cd206双特异性抗体及其制备方法和应用 |
CN113980907B (zh) * | 2021-12-24 | 2022-03-15 | 山东兴瑞生物科技有限公司 | 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用 |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
WO2023165514A1 (zh) * | 2022-03-01 | 2023-09-07 | 江苏恒瑞医药股份有限公司 | 特异性结合flt3和cd3的抗原结合分子及其医药用途 |
WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
WO2023242769A1 (en) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
WO2024009191A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
WO2024030888A2 (en) * | 2022-08-01 | 2024-02-08 | Yale University | Tnfr2 antibodies and methods of using the same |
WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
WO1993025698A1 (en) | 1992-06-10 | 1993-12-23 | The United States Government As Represented By The | Vector particles resistant to inactivation by human serum |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
WO1994023697A1 (en) | 1993-04-22 | 1994-10-27 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
CA2523216C (en) | 1993-09-15 | 2010-11-16 | Chiron Corporation | Recombinant alphavirus vectors |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DK0797676T3 (da) | 1993-10-25 | 2006-04-18 | Canji Inc | Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf |
CA2176712C (en) | 1993-11-16 | 2000-05-23 | Mantripragada Sankaram | Synthetic membrane vesicles with controlled release of encapsulated biologically active substances |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
ATE424463T1 (de) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
PT1575517E (pt) | 2002-12-24 | 2012-05-28 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
CA2569240A1 (en) | 2004-06-01 | 2005-12-15 | Domantis Limited | Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin |
EP1871417B1 (en) | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
US9023996B2 (en) | 2009-12-23 | 2015-05-05 | Synimmune Gmbh | Anti-FLT3 antibodies |
US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
JP6441079B2 (ja) * | 2011-12-19 | 2018-12-19 | シンイミューン ゲーエムベーハー | 二重特異性抗体分子 |
US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
EP3029067A1 (en) * | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
RU2739617C2 (ru) * | 2015-03-09 | 2020-12-28 | Эдженсис, Инк. | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3 |
US9951144B2 (en) | 2015-04-08 | 2018-04-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD38 |
CN114773476A (zh) | 2015-04-13 | 2022-07-22 | 辉瑞公司 | 治疗性抗体和它们的用途 |
TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
EP3352784A4 (en) * | 2015-09-23 | 2019-06-26 | Cytoimmune Therapeutics, LLC | FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY |
EP3630837A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc | Chimeric antigen receptors targeting flt3 |
-
2018
- 2018-05-31 EP EP18734624.2A patent/EP3630841A1/en active Pending
- 2018-05-31 TW TW111105166A patent/TWI790120B/zh active
- 2018-05-31 TW TW111148794A patent/TW202337907A/zh unknown
- 2018-05-31 KR KR1020197038745A patent/KR102356984B1/ko active IP Right Grant
- 2018-05-31 KR KR1020237006458A patent/KR20230035421A/ko not_active Application Discontinuation
- 2018-05-31 CN CN201880049293.9A patent/CN111247167A/zh active Pending
- 2018-05-31 TW TW107118828A patent/TWI757499B/zh active
- 2018-05-31 KR KR1020227002509A patent/KR102505349B1/ko active IP Right Grant
- 2018-05-31 US US15/993,874 patent/US11421040B2/en active Active
- 2018-05-31 CA CA3006798A patent/CA3006798A1/en active Pending
- 2018-05-31 BR BR112019025243-6A patent/BR112019025243A2/pt unknown
- 2018-05-31 AU AU2018275359A patent/AU2018275359C1/en active Active
- 2018-05-31 WO PCT/IB2018/053908 patent/WO2018220584A1/en active Application Filing
- 2018-05-31 MX MX2019014465A patent/MX2019014465A/es unknown
- 2018-05-31 JP JP2019565897A patent/JP7234142B2/ja active Active
- 2018-05-31 PE PE2019002483A patent/PE20191846A1/es unknown
- 2018-05-31 RU RU2019138710A patent/RU2758513C2/ru active
-
2019
- 2019-11-22 PH PH12019502640A patent/PH12019502640A1/en unknown
- 2019-12-02 IL IL271110A patent/IL271110A/en unknown
- 2019-12-02 CO CONC2019/0013611A patent/CO2019013611A2/es unknown
-
2022
- 2022-06-24 US US17/849,467 patent/US20230059489A1/en active Pending
-
2023
- 2023-02-22 JP JP2023026588A patent/JP2023075160A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018275359B2 (en) | 2021-07-01 |
PH12019502640A1 (en) | 2020-07-13 |
BR112019025243A2 (pt) | 2020-07-14 |
RU2019138710A3 (es) | 2021-07-12 |
TWI757499B (zh) | 2022-03-11 |
JP2020521481A (ja) | 2020-07-27 |
KR102356984B1 (ko) | 2022-01-28 |
AU2018275359A1 (en) | 2019-12-12 |
US20180346601A1 (en) | 2018-12-06 |
TW202337907A (zh) | 2023-10-01 |
PE20191846A1 (es) | 2019-12-31 |
TW201902933A (zh) | 2019-01-16 |
JP2023075160A (ja) | 2023-05-30 |
CA3006798A1 (en) | 2018-12-02 |
US11421040B2 (en) | 2022-08-23 |
CO2019013611A2 (es) | 2020-01-17 |
EP3630841A1 (en) | 2020-04-08 |
TW202246352A (zh) | 2022-12-01 |
KR20200013248A (ko) | 2020-02-06 |
JP7234142B2 (ja) | 2023-03-07 |
RU2758513C2 (ru) | 2021-10-29 |
AU2018275359C1 (en) | 2022-02-03 |
KR102505349B1 (ko) | 2023-03-02 |
KR20230035421A (ko) | 2023-03-13 |
TWI790120B (zh) | 2023-01-11 |
WO2018220584A1 (en) | 2018-12-06 |
US20230059489A1 (en) | 2023-02-23 |
RU2019138710A (ru) | 2021-07-12 |
KR20220018607A (ko) | 2022-02-15 |
IL271110A (en) | 2020-01-30 |
CN111247167A (zh) | 2020-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502640A1 (en) | Antibodies specific for flt3 and their uses | |
PH12020551153A1 (en) | Antibodies specific for cd70 and their uses | |
MY194642A (en) | Antibodies binding to cd3 | |
PH12020551211A1 (en) | Antibodies binding to gprc5d | |
EA201990171A1 (ru) | Биспецифичное антитело против egfr и против cd3 и его применения | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
PH12019500545A1 (en) | Cd3 binding antibodies | |
MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
GEP20207162B (en) | Lag-3-binding molecules and methods of use thereof | |
MX2018016404A (es) | Anticuerpos de union a cd3. | |
PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
WO2018017864A3 (en) | Pvrig-binding agents and uses thereof | |
PH12019502637A1 (en) | Chimeric antigen receptors targeting flt3 | |
EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
MX2019015349A (es) | Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3). | |
PH12021550764A1 (en) | Trem2 stabilizing antibodies | |
CR20220256A (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
EP4219556A3 (en) | Human monoclonal antibodies specific for flt3 and uses thereof | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
PH12019502274A1 (en) | Antibodies binding to steap-1 | |
MX2019000963A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso. | |
MX2021012967A (es) | Anticuerpos y formulaciones de anti-cd38. | |
EA202092753A1 (ru) | Биспецифические антитела к bcma/cd3 и gprdc5d/cd3 для применения в лечении рака | |
MX2021015922A (es) | Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos. | |
AR112707A1 (es) | Anticuerpos específicos para flt3 y sus usos |